skip to Global Navigation Bar skip to main content


homeHome > In-License > Licensed Products

 Licensed Products

Pipeline
Product Launch T.C. Licensor Sales Category M/S M/P
Sales
In-licensing
Gliatilin Dec. 2001 Nootropics Italfarmaco/Italy 56 140 0.4 1
Gasmotin Feb. 2002 Gastroprokinetics Dainippon Sumitomo/Japan 18 168 0.11 1
Smecta Dec. 1991 Intestinal absorbant antidiarrheals Ipsen/France 9 11 0.82 1
Airtal Jun. 1995 Antirheumatic, nonsteroid Almirall/Spain 9 290 0.03 1
Erdos Jul. 1997 Expectorants Calao/Italy 12 147 0.08 2
Co-promotion/ Co-marketing
Olmetec Feb. 2005 Angiotensin-II antagonist Daiichi Sankyo/ Japan 53 512 0.1 3
Sevikar Jun. 2009 ANGIOTEN-II ANTAG, COMB Daiichi Sankyo/ Japan 51 512 0.1 4
Diabex Jul. 1986 Biguanide antidiabetics Merck Sante 18 77 0.23 1
Ultracet Jun. 2009 Non-narcotic analgesics Janssen 22 185 0.12 1
Januvia Sep. 2008 DPP-IV inhibitors Plain MSD 43 109 0.39 1
Janumet Dec. 2008 DPP-IV inhibitors Comb MSD 51 92 0.55 1
Nexium Jun. 2009 Acid pump inhibitors Astrazeneca 42 214 0.2 1
Dulcolax March. 2010 Laxatives Boehringer Ingelheim 13 49 0.27 1

Source: IMS Korea 3Q, 2013

Sales Unit: USD million